Riverain™ Technologies Gains Approval from Australia’s Therapeutic Good Administration (TGA) for ClearRead™ Xray Confirm (Enhanced) and ClearRead CT

The company’s ClearRead Xray Confirm (Enhanced) and ClearRead CT – breakthrough lung nodule detection applications­ – have received clearance for sale in Australia.

Riverain Technologies – a US-based developer of AI-powered software that analyzes chest X-rays and CT images – announced Wednesday that the Therapeutic Goods of Australia (TGA) cleared more of the company’s AI solutions for sale and distribution in Australia, including ClearRead CT and ClearRead Xray Confirm (Enhanced). These solutions are joining ClearRead Xray Bone Suppress and ClearRead Xray Compare that have been TGA-cleared since 2009.

ClearRead solutions significantly improve a clinician’s ability to accurately and efficiently detect disease, suppressing vessels in thoracic CT and bone structures in chest X-ray images for earlier, more efficient detection of lung abnormalities. Powered by the most advanced machine learning and modeling methods available to the medical imaging market, the patented, FDA-cleared, CE marked, and now TGA-cleared software tools are deployable in the clinic or the Cloud:

• ClearRead Xray applications improve reading efficiency and accuracy and optimize the diagnostic value of all portable and upright images.
• ClearRead CT supports concurrent reading, allowing for faster reading with proven automatic nodule detection performance for all nodule types.

ClearRead solutions are in use globally, including Germany, Japan, Australia, Canada, and many institutions in the United States.